Seagen and Astellas Report P-Ib/II (EV-103) Cohort K Trial Results of Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) as 1L Treatment for Advanced Urothelial Cancer
Shots:
- The P-Ib/II (EV-103/KEYNOTE-869) cohort K trial evaluating Padcev + Merck’s Keytruda in patients with unresectable LA or mUC who are ineligible to receive cisplatin-based CT
- The 1EPs of the cohort K study showed a 64.5% confirmed ORR as per BICR, m-DOR was not reached in patients treated with enfortumab vedotin and pembrolizumab. The 2EPs include ORR per investigator assessment; DoR, DCR, PFS as per BICR and investigator assessment; OS; and assessment of safety
- The results were consistent with prior reported efficacy and safety results of the EV-103 dose-escalation cohort and expansion Cohort A. Additionally, the companies plan to discuss the results with regulatory authorities
Ref: Bussinesswire | Image: Seagen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
